• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

NEW GENRE Audio English-Spanish – Series B: Frontiers in Genomics Research

Series B: Frontiers in Genomics Research NEW GENRE Audio English-Spanish

View on Amazon.com

Spanish Series B

Fronteras de la investigación genómica

(3 book series) Kindle Edition 

by Larry H. Bernstein (Author) , Stephen J. Williams (Author) , Sudipta Saha (Author) , Ritu Saxena (Author) , Tilda Barliya (Author) , Anamika Sarkar (Author) , Marcus W. Feldman (Author) , Demet Sag (Author) , Prabodh kandala (Author) , Larry H. Bernstein (Author) , Aviva Lev-Ari (Author) , Madison Davis (Author)

Series URL

https://www.amazon.com/dp/B0BQGZYZVT?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn

Volume Titles & URL on Amazon.com

Volumen 1

Orientaciones genómicas para la medicina personalizada Orientaciones genómicas para la medicina personalizada (Serie B: Fronteras de la investigación genómica nº 1) (Spanish Edition)

http://www.amazon.com/dp/B0BQGZRQ2C

 

Volumen 2

Lo último en metodologías genómicas para agentes terapéuticos: edición génica, SMP y bioinformática, simulaciones y la ontología del genoma (Serie B: Fronteras … genómica nº 2) (Spanish Edition)

http://www.amazon.com/dp/B0BQH14CSF

 

 

Volume 3

Results of Medical Text Analysis with Natural Language Processing (NLP): Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, … de la investigación genómica Book 3) Kindle Edition

by Madison Davis (Author), Aviva Lev-Ari (Editor), Stephen J. Williams (Editor), Marcus W. Feldman (Editor)  Format: Kindle Edition

https://www.amazon.com/dp/B0BRD8JXTL

 

Volume’s Date of Publication, Price, Audio

 

Spanish Series B

 

Date of Publication

Spanish Edition Price

$305

English Edition

Price

 

Audio

Volumen 1

12/17/2022

56

75

No

Volumen 2

12/17/2022

94

125

Yes

Volume

3

12/29/2022

155

Did not exist

Not App

 

  • Original Volume One: Genomics Orientations for Personalized Medicine

On Amazon.com since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • NEW GENRE Volume One: Genomics Orientations for Personalized Medicine 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/new-genre-volume-one-genomics-orientations-for-personalized-medicine-series-b-volume-1/

PART A: The eTOCs in Spanish in Audio format

PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART C: The Editorials of the original e-Books in English in Audio format

View on Amazon.com

https://www.amazon.com/dp/B0BQGZRQ2C

 

  • Original Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology

On Amazon.com since 12/28/2019

https://www.amazon.com/dp/B08385KF87

  • New Genre Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology 

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/new-genre-volume-two-latest-in-genomics-methodologies-for-therapeutics-gene-editing-ngs-and-bioinformatics-simulations-and-the-genome-ontology-series-b-volume-2/

PART A:

A.1: The eTOCs in Spanish in Audio format AND

A.2: The eTOCs in Bi-lingual format: Spanish and English in Text format

PART B: The graphical results of Machine Learning (ML), Deep Learning (DL) and Natural Language Processing (NLP) algorithms AND the Domain Knowledge Expert (DKE) interpretation of the results in Text format – IS ISSUED AS A STANDALONE VOLUME: Volume Three  NEW GENRE Volume Three in Series B.

PART C: The Editorials of the original e-Books in English in Audio format

View on Amazon.com

https://www.amazon.com/dp/B0BQH14CSF

 

 

  • Volume Three did not exist in the Original BioMed e-Series, Series B: Frontiers in Genomics Research

  • During production it was known as PART B of Genomics, Volume Two to be published in the NEW GENRE e-Series B. It was thought to be included in Volume Two. Due to number of plots involved, a standalone volume for NLP Results and Interpretation was born, aka, Volume Three.

  • NEW GENRE Volume Three: Results of Medical Text Analysis with Natural Language Processing (NLP).  It is known in 2022, as Genomics Volume Three in NEW GENRE Series B: Frontiers in Genomics Research

https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-b-frontiers-in-genomics-research/genomics-volume-2-results-of-medical-text-analysis-with-natural-language-processing-nlp/

View on Amazon.com

https://www.amazon.com/dp/B0BRD8JXTL

 

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

This page has the following sub pages.

  • NEW GENRE Volume One: Genomics Orientations for Personalized Medicine – Series B, Volume 1
  • NEW GENRE Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology – Series B, Volume 2
  • NEW GENRE Genomics Volume Three, Results of Medical Text Analysis with Natural Language Processing (NLP) – Series B, Volume 3

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,056 other subscribers
  • Recent Posts

    • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UC, Berkeley, 1983. January 31, 2026
    • 2026 World Economic Forum, 1/19 – 1/23/2026, Davos, Switzerland, LPBI Group’s KOLs interpretation of AI in Health Videos January 24, 2026
    • Evolving LPBI Group’s Portfolio of Intellectual Properties (IP): From 2021 Vision to 2026 Reality January 12, 2026
    • Aviva Lev-Ari, PhD, RN – Biography ->> Grokepedia Entry January 11, 2026
    • List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
    • Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
    • Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com January 10, 2026
    • The youngest leader in AI in Health: Tanishq Mathew Abraham, Ph.D. (@iScienceLuvr) January 8, 2026
    • 2026 Grok Multimodal Causal Reasoning on Proprietary Cariovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage January 6, 2026
    • Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods January 6, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


Loading Comments...

    %d